Law360, New York (October 06, 2009) -- Giving heart to the pharmaceutical industry, the European Union’s highest court has ordered regulators to reconsider whether GlaxoSmithKline PLC should be exempted from antitrust law and allowed to raise prices against discounted trade among member countries.
The Court of Justice of the European Communities on Tuesday upheld the lower court, saying the European Commission failed to adequately weigh GlaxoSmithKline’s claim that the exploitation of uneven prices...
